BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27333990)

  • 1. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
    Rabi T; Catapano CV
    Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel synthetic oleanane triterpenoid AMR-MeOAc inhibits K-Ras through ERK, Akt and survivin in pancreatic cancer cells.
    Rabi T; Venkatanarashiman M
    Phytomedicine; 2014 Mar; 21(4):491-6. PubMed ID: 24215674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
    Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
    PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eicosapentaenoic Acid Inhibits
    Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
    Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels.
    Sato K; Hikita H; Myojin Y; Fukumoto K; Murai K; Sakane S; Tamura T; Yamai T; Nozaki Y; Yoshioka T; Kodama T; Shigekawa M; Sakamori R; Tatsumi T; Takehara T
    PLoS One; 2020; 15(7):e0235573. PubMed ID: 32609742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling.
    Chen L; Feng D; Qian Y; Cheng X; Song H; Qian Y; Zhang X; Wu Y; Lv H; Liu Q; Cheng G; Yang B; Gu M
    Phytomedicine; 2021 May; 85():153537. PubMed ID: 33744595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
    Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
    Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
    Chen J; Ouyang ZG; Zhang SH; Zhen YS
    Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
    Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
    Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells.
    Zhao C; Xiao H; Wu X; Li C; Liang G; Yang S; Lin J
    Oncotarget; 2015 Jun; 6(16):14472-87. PubMed ID: 25961376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo.
    Shi XH; Liang ZY; Ren XY; Liu TH
    Cancer Gene Ther; 2009 Mar; 16(3):227-36. PubMed ID: 18949011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-ras-driven engineered mouse models for pancreatic cancer.
    Yin X; Su J; Zhou X; Guo J; Wei W; Wang Z
    Discov Med; 2015 Jan; 19(102):15-21. PubMed ID: 25636957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.
    Albury TM; Pandey V; Gitto SB; Dominguez L; Spinel LP; Talarchek J; Klein-Szanto AJ; Testa JR; Altomare DA
    Neoplasia; 2015 Feb; 17(2):175-82. PubMed ID: 25748236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways.
    Zhang JG; Zhao G; Qin Q; Wang B; Liu L; Liu Y; Deng SC; Tian K; Wang CY
    Pancreatology; 2013; 13(2):140-6. PubMed ID: 23561972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diarylidenylpiperidones, H-4073 and HO-3867, Induce G2/M Cell-Cycle Arrest, Apoptosis and Inhibit STAT3 Phosphorylation in Human Pancreatic Cancer Cells.
    Mast JM; Tse D; Shee K; Lakshmi Kuppusamy M; Kmiec MM; Kálai T; Kuppusamy P
    Cell Biochem Biophys; 2019 Jun; 77(2):109-119. PubMed ID: 31089934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer.
    Wang X; Sheng W; Wang Y; Li L; Li Y; Zhang S; Liu X; Chen S; Zhen Y
    Mol Pharm; 2018 Jun; 15(6):2403-2412. PubMed ID: 29757658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.
    Liu S; Gandler HI; Tošić I; Ye DQ; Giaccone ZT; Frank DA
    Mol Cancer Res; 2021 Aug; 19(8):1283-1295. PubMed ID: 33931487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.